Fixing a leaky tricuspid valve

In 2024, the FDA approved two catheter-based devices for treating a leaky tricuspid valve. Both relieve symptoms and improve quality of life for people with moderate to severe tricuspid regurgitation, which affects about 4% of people ages 75 and older. One device is a modification of a system to treat mitral valve regurgitation that works by bringing the valve leaflets together at the areas of most severe leakage. The other device delivers a new valve made of cow heart tissue, which is commonly used in surgical valve replacements.